• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Is the FDA to blame for a 10% drop in early-stage investment in med-tech? | MassDevice.com On Call

Is the FDA to blame for a 10% drop in early-stage investment in med-tech? | MassDevice.com On Call

September 7, 2011 By MassDevice staff

MassDevice On Call

MASSDEVICE ON CALL — A series of high-profile drug and device recalls has locked the FDA in defense mode, making standard review processes more difficult, venture capitalists say.

The unpredictability and threat of longer review times may be making investors more wary of putting their faith and their dollars into med-tech.

Sign up to get our free newsletters delivered right to your inbox.

"We’ve seen a pretty steady and significant decline in early stage investment in med devices that really isn’t there for the rest of the industry," Dow Jones VentureSource global research director Jessica Canning told CNN. "And what it essentially boils down to is that uncertainty strangles innovation."

The FDA has repeatedly denied any internal culture change that would put medical devices in a more difficult position, but MelaSciences CEO Joe Gulfo’s tale of a sudden shift in the company’s relationship with the FDA that has left its flagship melanoma diagnostic device in limbo suggests otherwise.

Despite a 98 percent effectiveness rate in clinical trials and a step-by-step, binding agreement detailing the MelaFind device’s pathway to the U.S. market, the FDA found problems with trial data bucked the agreement.

MelaFind just won CE Mark approval in the European Union, according to the Associated Press.

Weight-loss surgery cheaper than non-operative care?

Despite the frequent need for additional operations for patients who have undergone bariatric weight-loss surgery, bariatric surgery is a more cost-effective way of handling morbid obesity than more traditional methods, according to a study published in the British Journal of Surgery.

Mass. Governor Patrick mingles with Boston’s med-tech scene

Mass. Governor Deval Patrick will joined the Mass. Life Sciences Center to launch EarlySense Inc.’s contact-free patient monitoring system at MetroWest Medical Center as EarlySense announced its move to Waltham, Mass., according to a press release.

Doctors: American Medical Assn. doesn’t speak for us

Only 13 percent of physician’s reportedly agree with the American Medical Assn.’s stance in support of President Barack Obama’s health care overhaul in a survey of 1,611 doctors by Jackson & Coker, a division of Jackson Healthcare, according to a press release.

DNA testing goes to space

Researchers plan to test a new DNA analyzer in zero gravity conditions using one of NASA’s "vomit comets," according to a press release.

Filed Under: Diagnostics, Healthcare Reform, News Well, Patient Monitoring, Research & Development Tagged With: American Medical Assn., EarlySense, MELA Sciences Inc.

More recent news

  • Real-world data backs Route 92 reperfusion system
  • LivsMed unveils new surgical robot with telesurgery capabilities
  • JenaValve enrolls first patient in TAVR for AR study
  • HistoSonics expands insurance coverage for histotripsy treatment
  • Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy